S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas

Despite marked success in treatment with immune checkpoint inhibitor (CPI), only a third of patients are responsive. Thus, melanoma still has one of the highest prevalence and mortality rates; which has led to a search for novel combination therapies that might complement CPI. Aberrant methylomes ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehdi, A., Attias, M., Arakelian, A., Szyf, M., Piccirillo, C.A., Rabbani, S.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840362/
https://www.ncbi.nlm.nih.gov/pubmed/36638586
http://dx.doi.org/10.1016/j.neo.2022.100874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840362/
https://www.ncbi.nlm.nih.gov/pubmed/36638586
http://dx.doi.org/10.1016/j.neo.2022.100874

Ejemplares similares